Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Pelemans

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Biochemical Pharmacology|March 27, 1998
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine)J Balzarini, H Pelemans, G Riess, et al.
The Journal of Infectious Diseases|November 14, 1997
Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudineJ Balzarini, H Pelemans, G Riess, et al.
Molecular Pharmacology|August 1, 1996
Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replicationJ Balzarini, H Pelemans, S Aquaro, et al.
Molecular Pharmacology|May 1, 1996
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidineJ Balzarini, H Pelemans, M J Pérez-Pérez, et al.
Journal of Virology|October 29, 1997
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1H Pelemans, R Esnouf, A Dunkler, et al.
Journal of Medicinal Chemistry|June 1, 2001
Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptaseF Rodríguez-Barrios, C Pérez, E Lobatón, et al.
Virology|February 13, 2001
Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138H Pelemans, A Aertsen, K Van Laethem, et al.
AIDS Research and Human Retroviruses|June 30, 2000
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patientsK Van Laethem, J C Schmit, H Pelemans, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Biochemical Pharmacology|March 27, 1998
Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine)J Balzarini, H Pelemans, G Riess, et al.
The Journal of Infectious Diseases|November 14, 1997
Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudineJ Balzarini, H Pelemans, G Riess, et al.
Molecular Pharmacology|August 1, 1996
Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replicationJ Balzarini, H Pelemans, S Aquaro, et al.
Molecular Pharmacology|May 1, 1996
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidineJ Balzarini, H Pelemans, M J Pérez-Pérez, et al.
Journal of Virology|October 29, 1997
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1H Pelemans, R Esnouf, A Dunkler, et al.
Journal of Medicinal Chemistry|June 1, 2001
Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptaseF Rodríguez-Barrios, C Pérez, E Lobatón, et al.
Virology|February 13, 2001
Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138H Pelemans, A Aertsen, K Van Laethem, et al.
AIDS Research and Human Retroviruses|June 30, 2000
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patientsK Van Laethem, J C Schmit, H Pelemans, et al.
Pageof 2